Shared Pharmacotherapeutic Strategies for Cannabinoid & Opioid Use Disorders

大麻素的共同药物治疗策略

基本信息

批准号：
9098672
负责人：
Frances Rudnick Levin
金额：
$ 289.4万
依托单位：
NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-09-01 至 2019-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9098672
关键词：
Abstinence Achievement Algorithms Behavioral Buprenorphine Cannabidiol Cannabinoids Cannabis Clinic Clinical Clinical Trials Combination Medication Cost Control Development Discipline Disease Doxazosin Drops Drug Use Disorder Educational Activities Effectiveness Ensure FDA approved Faculty Geographic state Human Laboratories Laboratory Study Marijuana Mentors Mission Nabilone Naltrexone Neurobiology Opioid Opioid Analgesics Patients Pharmaceutical Preparations Pharmacological Treatment Phase Phase II Clinical Trials Pilot Projects Qualifying Relapse Research Research Personnel Research Support Resources Role Running Scientist Signal Transduction Statistical Data Interpretation Substance abuse problem Sum TNFRSF5 gene Testing Time Training Training Activity Training and Education Translating Vertebral column Withdrawal Work base cannabinoid treatment clinical practice control trial cost efficient data management evidence base illicit drug use improved innovation marijuana legalization marijuana use marijuana use disorder next generation novel novel strategies opioid use opioid use disorder organizational structure programs public health relevance screening success

项目摘要

DESCRIPTION (provided by applicant): There is substantial need for improving the effectiveness of medications for treating opioid use disorder (OUD), plus a considerable need to develop effective medications for cannabis use disorder (CUD). The novel overarching theme of this Center is to examine medications based on their ability to improve clinical sequelae common to both cannabinoid and opioid use disorders (i.e., abstinence-induced withdrawal and relapse), in part due to their shared common neurobiologic underpinnings. This Center consists of 4 Cores and 4 Projects with considerable synergy and interdependency. Unifying all of the Projects are the Administrative Core, the Research Core, the Pilot Project Core, and the Training and Education Core. In the first 2.5 years of this Center, Phase II clinical trials in Project 2 and Project 4 will test the combined cannabinoid/opioid strategy of combining nabilone and naltrexone for both CUD and OUD. Meanwhile, the human laboratory studies in Project 1 and Project 3 will evaluate medications (lorcaserin, cannabidiol, doxazosin, and zonisamide, potentially in combination with nabilone or buprenorphine or sustained-release naltrexone) using a priori decision algorithms to identify candidate medications to be tested in subsequent Phase II clinical trials in Projects 2 and 4. The Center has a clear organizational structure and will b conducted in a cost-efficient manner. The resources available to the research team, along with the institutional support, ensure the success in attaining the Aims of the Center. These include: 1) Use of efficient decision algorithms to test medications alone, and in combination, in the laboratory and move those that show a "positive" signal rapidly into the clinic; 2) Test these "positive" medications from the laboratory for efficacy in Phase II controlled trials; 3) Explore predictors of medication effects in the laboratory and clinic settings; 4) Train junior investigatos to become the next generation of leaders in substance abuse; and 5) Disseminate evidence-based research findings locally, nationally and internationally. This application builds on the strengths and achievements of our research team, while developing innovative advances in shared medications development for cannabinoids and opioids. Our innovative approach will ensure that our Center is synergistic, translational and at the cutting edge of medications development. In sum, this Center is strongly focused on using the most efficient approach to find potential pharmacologic agents to treat two disorders that are of great clinical concern, namely, cannabis and opioid use disorders.

描述（由申请人提供）：提高药物治疗阿片类药物使用障碍（OUD）的有效性，以及开发有效的大麻使用障碍药物（CUD）的有效性。该中心的新型总体主题是根据药物改善大麻素和阿片类药物使用障碍共有的临床后遗症的能力（即禁欲引起的戒断和复发），部分原因是它们共同的共同神经生物学基础。该中心由4个核心和4个具有相当协同和相互依赖的项目组成。统一所有项目是行政核心，研究核心，试点项目核心以及培训和教育核心。在该中心的前2。5年中，项目2和项目4的II期临床试验将测试CUD和OUD的Nabilone和Naltrexone合并的大麻素/阿片类药物策略。同时，项目1和项目3中的人类实验室研究将评估药物（Lorcaserin，Cannabidiol，Doxazosin和Zonisamide，有可能与Nabilone或buprenorphine或buprenorphine或持续释放的Naltrexone结合使用，使用先验的决策）来确定候选药物的临时性临时性临时性临时性，以确定候选药物的临时性II阶段，并在后期进行了试验。结构并将以成本效益的方式进行B。研究团队可用的资源以及机构支持，确保了达到中心目标的成功。其中包括：1）在实验室中使用有效的决策算法单独测试药物，并将其组合起来，并将显示出“正”信号的人迅速进入诊所； 2）在II期对照试验中测试实验室的这些“阳性”药物； 3）探索实验室和诊所环境中用药效应的预测因素； 4）训练初级调查成为滥用毒品的下一代领导人； 5）在本地，国内和国际上传播基于证据的研究发现。该应用程序以我们研究团队的优势和成就为基础，同时在共享大麻素和阿片类药物共享药物开发方面的创新进展。我们的创新方法将确保我们的中心具有协同，转化和药物开发的最前沿。总而言之，该中心强烈专注于使用最有效的方法来寻找潜在的药理剂来治疗两种临床关注的疾病，即大麻和阿片类药物使用障碍。